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Abstract 
Apoptotic ell death is a complex process whose biochemistry is poorly understood. Direct exposure of various cell types to oxidants 
such as hydrogen peroxide or lipid hydroperoxides can directly induce apoptosis, while in many experimental models pretreatment of 
cells with antioxidants has been shown to protect against his form of cell death. Recent experimental evidence suggests that multiple 
forms of thymocyte apoptosis can be inhibited by free radical spin traps, spin probes and thiol reductants, and that this inhibition 
correlates with a lower oxidative burden within the treated cells. Possible sites of production of these oxidants include mitochondrial 
electron transport and phospholipase A2-activated arachidonic acid metabolism, while intracellular targets may include redox sensitive 
transcription factors and inhibitory proteins that must be tagged for proteolysis before apoptosis can commence. 
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1. Introduction 
Apoptosis is a form of cell death in which an individual 
cell undergoes an internally controlled transition from an 
intact metabolically active state into a number of shrunken 
remnants retaining their membrane bound integrity [1,2]. 
Lysis of internal organelles apparently does not occur 
during this process, and little external leakage of the 
contents of the dying cell can be detected. As a conse- 
quence, apoptotic cells do not induce an inflammatory 
response in vivo. Instead the shrunken apoptotic bodies are 
phagocytosed by macrophages and their contents recycled 
[3]. Apoptosis therefore provides the organism both with a 
safe and efficient way to continuously turnover cells in any 
tissue, and the capability to remove specific cells during 
development. 
Cell culture studies have revealed a multitude of differ- 
ent ways in which apoptotic cell death can be induced. 
Examples include ligation of various cell surface receptors, 
elevation of intracellular Ca 2+, chelation of intracellular 
Zn 2÷, irradiation, inhibition of topoisomerase II, oxidative 
stress, growth factor deprivation and glucocorticoid treat- 
ment [4,5]. A diverse array of initial intracellular distur- 
bances can therefore engage apoptosis in any given cell. 
However, the biochemical mechanisms underlying the 
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common morphological events that subsequently occur are 
poorly understood. 
2. External oxidants induce apoptosis 
Direct exposure of cells to oxidants such as hydrogen 
peroxide or various redox-active quinones causes multiple 
intracellular alterations, including elevation of cytosolic 
Ca 2+, energy depletion, and oxidation of glutathione, 
NADPH, protein thiols and lipids (reviewed in Ref. [6]). 
Necrosis is the characteristic end point of such a dramatic 
disturbance in cell homeostasis. As apoptosis and necrosis 
represent such distinct pathways to cell death, the involve- 
ment of oxidants in apoptosis was initially ignored. How- 
ever, it is now apparent that under certain conditions low 
level exposure of cells to oxidants triggers apoptosis rather 
than necrosis, and, more interestingly, that oxidants may 
be essential biochemical intermediates in the progression 
of many forms of apoptosis. 
One of the first examples that direct oxidant treatment 
could cause apoptosis was provided by the observation that 
low concentrations of hydrogen peroxide induce apoptosis 
in HL-60 cells, while necrosis occurs when millimolar 
amounts of the oxidant are present [7]. Very similar results 
have recently been obtained in this laboratory with the 
observation that exposure of rat insulinoma RINm5F cells 
to increasing doses of 2,4-dimethoxy-l,4-napthoquinone 
progressively results in cell proliferation, apoptosis and 
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finally necrosis [8]. Oxidised low density lipoproteins and 
lipid hydroperoxides such as 15-hydroperoxyeicosatetra- 
enoic acid are other oxidants reported to induce apoptosis 
when directly applied to cells [9,10]. In common with a 
variety of other reagents oxidants can thus activate apopto- 
sis, although the manner in which they engage this path- 
way in a responding cell is not understood. 
3. Antioxidants protect cells against many different 
forms of apoptosis 
Antioxidants have been reported to provide protection 
against many different ypes of apoptosis [11]. This is not 
just confined to the direct oxidant-induced cell deaths 
referred to above, but also to receptor- and growth factor- 
mediated forms of apoptosis. For example, apoptosis in- 
duced by the cytokine tumour necrosis factor a (TNF-a) 
can be prevented by antioxidants such as N-acetyl cysteine 
(NAC) and thioredoxin [12-15]. Thiol reductants have 
been shown to have similar protective effects against 
anti-FAS antibody/FAS antigen-induced apoptosis [14], 
while the radioprotective agent N-(2-mercaptoethyl)-l,3- 
propanediamine has been reported to reduce thymocyte 
apoptosis following either irradiation or exposure to Ca 2+ 
ionophore [16]. We have recently found that the endoge- 
nous thiol dihydrolipoic acid (but not its oxidised counter- 
part lipoic acid) can also significantly reduce apoptosis in 
rat thymocytes exposed to either methylprednisolone or 
etoposide (Bustamante etal., unpublished ata). This inhi- 
bition was manifest morphologically as a reduction in the 
number of apoptotic bodies formed, and also by the pre- 
vention of cell shrinkage and nuclear chromatin degrada- 
tion. These findings suggest hat oxidation plays a role in 
the progression of apoptosis in many different model 
systems. 
Further evidence in support of this hypothesis has come 
from studies with the Bcl-2 protein. This protooncogene 
was discovered at the t(14;l 8) chromosomal breakpoint in 
some human follicular lymphomas, where juxtaposition of 
the bcl-2 gene alongside an immunoglobulin heavy chain 
promoter results in an overexpression f the protein [17]. 
Within cells Bcl-2 is localised to mitochondrial, endoplas- 
mic reticular and nuclear membranes [18,19], where it 
dimerizes with a structurally-related protein called Bax 
[20]. Overexpression f the Bcl-2 protein has been shown 
to suppress apoptosis induced by multiple stimuli, includ- 
ing glucocorticoids, irradiation, chemotherapeutic agents, 
growth factor deprivation and TNF-a [21-24]. It has been 
suggested that Bcl-2 inhibits cell death by reducing the 
generation of reactive oxidants [25,26], and thereby pre- 
venting a critical intracellular oxidation(s) that is presum- 
ably necessary if apoptosis is to occur. Lam et al. [27] have 
recently reported that Bcl-2 can also interfere with the 
release of Ca 2+ from intracellular stores, and given the 
complex inter-relationships that exist between cytoplasmic 
Ca 2+ levels and the generation of oxidants the two find- 
ings may be linked [27]. 
Using rat thymocytes, we and others have found that 
free radical spin traps can also inhibit multiple forms of 
apoptosis [51,52]. The nitroso-containing spin trap 5,5-di- 
methyl-l-pyrroline-N-oxide (DMPO) inhibits apoptosis in- 
duced by methylprednisolone, the Zn 2 + chelator 
N,N,N ' ,N ' - te t rak is (2 -pyr idy lmethy l )e thy lened iamine ,  the 
Ca 2+ ATPase inhibitor thapsigargin, and the topoiso- 
merase II inhibitor etoposide (ICs0 between 15 and 20 mM 
DMPO in each case). The nitroxide radical 2,2,6,6-tetra- 
methyl-l-piperidinyloxy (TEMPO) is another antioxidant 
that we have found to possess effective anti-apoptotic 
properties in all four of the systems listed above (ICs0 
about 0.5-2 mM TEMPO). The effects of both anti- 
oxidants are manifest as a prevention of cell shrinkage and 
a reduction in internucleosomal fragmentation of chro- 
matin, the two most characteristic ndicators of apoptosis 
in these cells. When thymocytes undergoing lucocorti- 
coid-induced apoptosis were separated by Percoll density 
centrifugation, an increased level of oxidation (measured 
as a depletion in reduced glutathione and an increase in 
peroxide content) was detectable in both pre-apoptotic and 
apoptotic ells [51]. Co-incubation with TEMPO reduced 
the number of thymocytes undergoing these oxidative 
changes at the same concentration as it exerted an in- 
hibitory effect on apoptosis. These results add support o 
the hypothesis that intracellular oxidants play an important 
role in apoptosis, although neither the identity, site of 
generation or molecular targets of the putative oxidant 
species have been identified. 
4. Site of production of oxidants during apoptosis 
Mitochondrial oxidative phosphorylation is one of the 
major sites of production of reactive oxygen species (ROS) 
in eukaryotic ells [28]. Treatment of various cells with 
TNF-a is known to increase the production of ROS by 
mitochondria [29,30]. Although most cells possess suffi- 
cient antioxidant defences to overcome the necrotic poten- 
tial of these oxidants (exceptions include L929 cells prein- 
cubated with protein synthesis inhibitors), TNF-a treated 
cells often undergo apoptosis on a longer time scale [31- 
34]. The observation that thiol reductants inhibit this sec- 
ondary cell death [13,14] suggests that mitochondrially- 
derived ROS may have a signaling role in apoptosis. In 
support of this hypothesis, over expression of the mito- 
chondrial enzyme manganous uperoxide dismutase has 
been shown to confer cells with resistance to the toxic 
effects TNF-a [35]. Overexpression f the same enzyme 
also promotes cell survival following irradiation or expo- 
sure to DNA intercalating drugs [36], indicating that ROS 
produced by mitochondria may be important in other 
examples of apoptosis. 
It is unlikely, however, that ROS originating from 
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mitochondria re common mediators of apoptosis. Mito- 
chondrial DNA was observed to remain intact during 
glucocorticoid-induced thymocyte apoptosis [37], which 
given the high sensitivity of mitochondrial DNA to free 
radical scission [38] suggested that this organelle was not 
producing abnormally large amounts of ROS. In addition, 
it has been shown that fibroblasts depleted of mitochon- 
drial DNA (and thereby lacking the capacity for oxidative 
phosphorylation) undergo apoptosis at approximately the 
same rate as wild-type cells [39]. If oxidants are important 
in apoptosis, and the experiments ummarised previously 
suggest that they are, then in many cases they must be 
derived from non-mitochondrial sources. One possibility is 
arachidonic acid metabolism triggered by the Ca2+-depen - 
dent enzyme phospholipase A 2, while another is cy- 
tochrome P-450. Alternatively, the loss of function of 
cytoplasmic opper/z inc superoxide dismutase could also 
provide an increased oxidative burden within cells. Anti- 
sense oligonucleotide-induced down regulation of this en- 
zyme has been shown to promote apoptosis in two differ- 
ent neuronal cell culture systems [40,41]. The increase in 
cell death was blocked in the presence of NAC [40], and it 
is therefore probable that an increased half life of the 
superoxide radical was indeed responsible for inducing 
apoptosis in these cells. It should be emphasised however 
that, independent of the source of the ROS, functional 
mitochondria would still be needed to supply ATP. For 
example, etoposide-induced apoptosis is reduced in the 
presence of dinitrophenol (which uncouples ATP synthesis 
from oxidative phosphorylation [42]), while the experiment 
described above with cells depleted of mitochondrial DNA 
had to be performed in the presence of high concentrations 
of extracellular pyruvate to supplement non-mitochondrial 
ATP synthesis [39]. 
Jun [47]), with thiol oxidation causing a large decrease in 
the efficiency of DNA binding. In contrast, DNA binding 
activity of the nuclear factor kappa B (NFK B) is indirectly 
activated by oxidative events (via enhanced proteolysis of 
its inhibitory factor I K B), thereby initiating transcription 
of NFKB responsive genes [48-50]. Oxidation therefore 
has the potential to alter the phenotype of a cell via 
changes in gene transcription, and at least in some situa- 
tions this may provide an entrance into apoptosis. 
6. Summary 
In summary, intracellular oxidation may play a more 
central role in apoptotic cell death than has hitherto been 
assumed. Not only can direct exposure of cells to a mild 
oxidative stress induce apoptosis, but antioxidants (includ- 
ing intracellular proteins such as thioredoxin, manganous 
superoxide dismutase and possibly bcl-2) also protect cells 
against apoptosis induced by various stimuli that do not 
exert a direct oxidant effect. This hypothesis requires that 
stimuli such as glucocorticoids or topoisomerase II in- 
hibitors somehow activate oxidative events within the re- 
sponding cell, although it is unclear how this could occur. 
It is unlikely that these putative oxidants originate from a 
single source. In different situations perhaps mitochondrial 
electron transport (e.g., after TNF-o~ stimulation) or Ca 2÷- 
activated arachidonic acid metabolism (e.g., after Ca 2+ 
ionophore treatment) supplies the required oxidising agents. 
In each case, the resulting change in intracellular edox 
could then alter gene expression or modify pre-existing 
proteins (possibly via enhanced proteolysis), such that 
apoptosis occurs. 
5. Intracellular targets for oxidation during apoptosis 
Following their production, intracellular oxidants have 
the potential to trigger apoptosis in several ways, although 
in the absence of experimental data it is only possible to 
speculate. Firstly, it is likely that direct oxidative damage 
to DNA can initiate an apoptotic response, a possible 
example being radiation-induced apoptosis of lymphocytes 
[43,44]. Secondly, oxidation of intracellular proteins may 
modify either their function or their ability to be recog- 
nised by other proteins. For example, oxidative damage 
can increase the susceptibility of some proteins to degrada- 
tion by non-lysosomal proteinases complex [45]. Pro- 
teinase inhibitors are known to block thymocyte apoptosis 
[46], and it is possible that they are protecting the same 
intracellular target as antioxidants from degradation. Pro- 
tein oxidation may also be involved in changing nuclear 
gene transcription such that the apoptotic pathway is acti- 
vated. Several transcription factors have critical cysteine 
residues involved in DNA binding (for example Fos and 
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